MEET ANDREW

60-year-old male

Retired; spends a lot of time reading using an e-reader

Medical History

- **Referred by OD** after a recent routine appointment revealed **cataract development**
- **Proceeding with cataract surgery**
- A previous OD prescribed **Rx drops** within the last year (patient is unsure which ones); were **not considered helpful** and were **discontinued after 3 months**

Chief Complaints

- Recently, **vision has seemed "hazy,"** and vision is worse after **looking at a digital screen**
- Patient **avoids driving at night** and **during inclement weather,** when vision is most affected
- Patient reports a **burning and dry sensation**, like sand in the eyes, that is worse at the end of the day

Initial Observations

- **2+ NS** in each eye
- **Positive** glare test

NS, nuclear sclerosis.

INDICATION

MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO

Please see additional Important Safety Information on next page.

Click here for full Prescribing Information for MIEBO.

Miebo™
(perfluorohexyloctane ophthalmic solution)

MEET ANDREW

NEXT STEPS

Based on Andrew's history and presentation, **what assessments would you perform?**

What results would you expect to find?

What would be **your proposed treatment plan** to best optimize the ocular surface prior to surgery?

Discover how MIEBO could provide patients like Andrew with **relief from the signs and symptoms** of dry eye disease.

Learn more at MIEBO-ECP.COM.

IMPORTANT SAFETY INFORMATION (CONTINUED)

- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information on previous page.

Click here for full Prescribing Information for MIEBO.

BAUSCH + LOMB

MBO.0407.USA.23

Miebo™
(perfluorohexyloctane ophthalmic solution)